Pharmalive - The Pulse of the Pharmaceutical Industry
Search Criteria: Search In:  
Conferences


R&D Directions Insider

Wave of momentum for cancer immunotherapies

Friday, June 4th, 2010

Since the landmark approval of Provenge in late April for prostate cancer, much has been made of the significant buzz created for similar cancer immunotherapies (see stories here and here) that stimulate a patient’s immune system to recognize, attack, and kill tumor cells. Clinical data for a new wave of ...

   
©2012 UBM Canon